← All trials
NCT03866980
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 27, 2018
- Primary completion
- Nov 30, 2020
- Completion date
- Nov 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 360
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Akeso Pharmaceuticals, Inc.Lead sponsor
- People's Liberation Army of ChinaStudy chair
- Jiao Tong UniversityStudy chair
- Akeso Pharmaceuticals, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.